321 related articles for article (PubMed ID: 31900908)
1. Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy.
Prokhnevska N; Emerson DA; Kissick HT; Redmond WL
Adv Exp Med Biol; 2019; 1210():121-147. PubMed ID: 31900908
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
3. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
4. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
5. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
Stultz J; Fong L
Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953
[TBL] [Abstract][Full Text] [Related]
6. Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
Dawson NA; Roesch EE
Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer immunotherapy: where are we and where are we going?
De Velasco MA; Uemura H
Curr Opin Urol; 2018 Jan; 28(1):15-24. PubMed ID: 29095729
[TBL] [Abstract][Full Text] [Related]
8. The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer.
Nair SS; Weil R; Dovey Z; Davis A; Tewari AK
Urol Clin North Am; 2020 Nov; 47(4S):e17-e54. PubMed ID: 33446323
[TBL] [Abstract][Full Text] [Related]
9. Efficacy Against Human Prostate Cancer by Prostate-specific Membrane Antigen-specific, Transforming Growth Factor-β Insensitive Genetically Targeted CD8
Zhang Q; Helfand BT; Carneiro BA; Qin W; Yang XJ; Lee C; Zhang W; Giles FJ; Cristofanilli M; Kuzel TM
Eur Urol; 2018 May; 73(5):648-652. PubMed ID: 29275833
[TBL] [Abstract][Full Text] [Related]
10. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
de Almeida DVP; Fong L; Rettig MB; Autio KA
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-18. PubMed ID: 32343604
[TBL] [Abstract][Full Text] [Related]
12. Non-coding RNAs: Emerging roles in the characterization of immune microenvironment and immunotherapy of prostate cancer.
Yang F; Li J; Ge Q; Zhang Y; Zhang M; Zhou J; Wang H; Du J; Gao S; Liang C; Meng J
Biochem Pharmacol; 2023 Aug; 214():115669. PubMed ID: 37364622
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive review of immunotherapies in prostate cancer.
Maia MC; Hansen AR
Crit Rev Oncol Hematol; 2017 May; 113():292-303. PubMed ID: 28427519
[TBL] [Abstract][Full Text] [Related]
14. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for prostate cancer: False promises or true hope?
Rekoske BT; McNeel DG
Cancer; 2016 Dec; 122(23):3598-3607. PubMed ID: 27649312
[TBL] [Abstract][Full Text] [Related]
16. Is There a Role for Immunotherapy in Prostate Cancer?
Rizzo A; Mollica V; Cimadamore A; Santoni M; Scarpelli M; Giunchi F; Cheng L; Lopez-Beltran A; Fiorentino M; Montironi R; Massari F
Cells; 2020 Sep; 9(9):. PubMed ID: 32911806
[TBL] [Abstract][Full Text] [Related]
17. A New Era of Immunotherapy in Prostate Cancer.
Pizzola C; Rizvi SM; Joshi M
Curr Mol Pharmacol; 2016; 9(3):217-225. PubMed ID: 26177645
[TBL] [Abstract][Full Text] [Related]
18. Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen.
Lopez-Bujanda ZA; Chaimowitz MG; Armstrong TD; Foote JB; Emens LA; Drake CG
Oncoimmunology; 2020 Sep; 9(1):1809926. PubMed ID: 33457094
[TBL] [Abstract][Full Text] [Related]
19. Identification of targets for prostate cancer immunotherapy.
Papanicolau-Sengos A; Yang Y; Pabla S; Lenzo FL; Kato S; Kurzrock R; DePietro P; Nesline M; Conroy J; Glenn S; Chatta G; Morrison C
Prostate; 2019 Apr; 79(5):498-505. PubMed ID: 30614027
[TBL] [Abstract][Full Text] [Related]
20. The requirement for immune infiltration and organization in the tumor microenvironment for successful immunotherapy in prostate cancer.
Jansen CS; Prokhnevska N; Kissick HT
Urol Oncol; 2019 Aug; 37(8):543-555. PubMed ID: 30446449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]